D. Mass. · No. 1:26-cv-14374
Full docket on CourtListener ↗
No federal docket timeline hydrated for this case yet (state-court settlements have no RECAP docket).
| Matter | Type | Practice area | Court | Date | Value |
|---|---|---|---|---|---|
| Fresenius Medical Care Holdings Inc.source ↗ filed by Milberg, PLLC · No. 1:26-cv-14374 · 28:1332 Diversity-Personal Injury · view case timeline → Comparable settlements $200M–$740M ▾No directly on-point false-advertising rulings against a healthcare/dialysis defendant exist in the comparable set; analogous consumer-fraud claims split, with Guthrie v. Transamerica affirming denial of class cert over individualized reliance issues while Cetorelli affirmed a full CSPA deceptive-practices verdict. Comparable settlements $200M–$740M median $274.75M · n=10 DiDi Global Inc. $740M · Merck & Co. Inc. a $688M · Toyota Industries $436M Per member (realized): ~$2,500 median · $2,500–$2,500 (n=1) Comparable verdict: Papaya $420M · VPX, Inc. $293M Key precedent: Guthrie v. Transamerica Life Ins. Co. - shows courts often reject class treatment of advertising/labeling claims requiring individualized reliance inquiry, a likely defense here. Main risk: Class certification denial due to individualized reliance/communications issues, as in Guthrie, or standing/merits dismissal at MTD stage. Rough EV model (wide — class size is the big unknown, not a prediction): $35M–$350M Single realized per-member data point and no directly comparable false-advertising ruling against this defendant type make this estimate highly speculative. · grounded in 10 rulings, 10 settlements, 9 verdicts | Filing | False Advertising | D. Mass. | 2026-09-24 | $200M–$740M comparable settlements |